skip to main content

OVPA8

OVPA8

Catalogue No.

19062601

Cell Line Name

OVPA8

Cell Line Description

OVPA8 cell line is derived from ascitic fluid from a 47 year old platinum-treated patient with relapsed ovarian cancer (histologically confirmed high-grade serous ovarian cancer; adenocarcinoma papillare serosum, G3, FIGO IIIC). OVPA8 cells show morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation and loss of one copy of BRCA2. OVPA8 line has stable STR profile.

Characteristics

Tissue of Origin

Ovarian/Fallopian tube epithelium

Morphology

Epithelium

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10,11
D3S1358: 15
D5S818: 9,13
D7S820: 8,9
D8S1179: 14
D13S317: 11
D16S539: 12,14
D18S51: 12
D21S11: 29,30
FGA: 22,25
Penta D: 13
Penta E: 5
TH01: 8
TPOX: 9,11
vWA: 14

Karyotype

Karyotype analysis was performed using classical G-banding technique. The chromosome count ranged from 57 to 67 per spread, with multiple aberrations and from 5 to 9 unidentified marker chromosomes.

Applications

For research only. OVPA8 was generated to offer a cell-based model system of human high-grade serous ovarian cancer. The cell line has defined chemosensitivity pattern. It is sensitive to paclitaxel (IC50 = 0.001 µm) and resistant to cisplatin (IC50 = 16.27 µM).

Disease

Adenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent (70-80%) cultures using 1:3 to 1:6 ratio. Detach cells from culture plate using 1x PBS (Ca²⁺/Mg²⁺-free) for 30 seconds, then 0.05% Trypsin/EDTA for 8-10 min. Seed cells at 1-2 x 10⁴/cm²; 5% CO₂; 95% air at 37°C. Cells have a doubling time of approximately 44h.

Culture Medium

RPMI 1640 supplemented with 10% Foetal Bovine Serum and 2 mM L-glutamine

Growth Mode

Adherent epithelial, low morphological heterogeneity, medium sized

Additional Info

Depositor

Katarzyna Lisowska Email: katarzyna.lisowska@io.gliwice.pl Tel: +48 (32) 278 98 88 Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie Institute - Oncology Centre, Gliwice Branch, ul. Wybrzeze Armii Krajowej 15, 44-101 Gliwice, Poland

Country of Origin

Denmark

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Tudrej., P et al. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8. Int J; Mol Sci. 2018, 19(7), PMID: 30018258

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: OVPA8 (ECACC 19062601).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.